Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Feb 2021

Subbiah V, Shen T, Terzyan S S, Liu X, Hu X, Patel K P, Hu M, Cabanillas M, Behrang A, Meric-Bernstam F, Vo P T T, Mooers B H M, Wu J

Abstract excerpt

BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung cancer (NSCLC). It is critical to analyze RET mutants resistant to these drugs and unravel the molecular basis to improve patient outcomes. PATIENTS AND METHODS: Cell-free DNAs (cfDNAs) were analyzed in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Share to Pyrazoles

Share to Pyridines

Share to Pyrimidines

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33161056
DOI: 10.1016/j.annonc.2020.10.599
PMCID: PMC7883646

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.PMID 33161056Read ↗

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read ↗

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.Semantic proximity Read ↗

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.Semantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

Treatment of non–small cell lung cancer with RET rearrangementsSemantic proximity Read ↗

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Semantic proximity Read ↗

Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based InhibitorsSemantic proximity Read ↗

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.Semantic proximity Read ↗

Mechanisms of resistance to RET-directed therapiesSemantic proximity Read ↗

Selpercatinib in the treatment of thyroid cancer.Semantic proximity Read ↗

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.Semantic proximity Read ↗

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.